Silo Pharma transmits three PCT patent applications to USPTO for psilocybin delivery

Silo Pharma, Inc.

Received notice of successful transmission to USPTO for three PCT patent applications.
Applications filed July 2021 relate to CNS-homing peptides delivering anti-inflammatory therapeutics with psilocybin.
National phase entries for these PCT applications are now at the USPTO.

item 8.01

Silo Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-003906

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.